Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Meta Expands AI Training With Employee Activity Tracking Tools 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
REDWOOD CITY, Calif., March 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 1, 2016, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 17,200 shares of the company’s common stock with a per share exercise price of $13.46, the closing trading price on the grant date, and 8,600 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
